Home/Pipeline/Cemdisiran

Cemdisiran

C5 Complement-mediated Diseases

Phase 2Active

Key Facts

Indication
C5 Complement-mediated Diseases
Phase
Phase 2
Status
Active
Company

About Alnylam Pharmaceuticals

Founded in 2002, Alnylam Pharmaceuticals is a leading biopharmaceutical company that pioneered the RNAi therapeutics revolution. The company leverages RNA interference technology to selectively silence genes that cause or contribute to disease, offering a fundamentally different approach to treating genetic disorders. With multiple approved therapies and a strong pipeline focused on rare diseases, Alnylam has established itself as the definitive leader in RNAi therapeutics with global reach and operations.

View full company profile